For instance, it can be investigated whether ISL can inhibit the metastatic progression of digestive system tumors by regulating the circNAV3/miR-4262/ST6GALNAC5/EGFR axis, which is analogous to ISL’s role in triple-negative breast cancer (Xie et al., 2025). Here, EGFR is linked to triple-negative breast carcinoma.